Skip to main content
OpenTrials
Completed

NCT Number: NCT06411912

A Study of NIDO-361 in Patients With SBMA

The purpose of this study is to evaluate the safety, tolerability, and efficacy of NIDO-361 in adult patients with Spinal and Bulbar Muscular Atrophy (SBMA).

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–70 year

Sex eligibility

Male

Study type

Interventional

Phase

Phase 2

Primary location

Rigshospitalet, Klinik for Nerve- og Muskelsygdomme & Copenhagen Neuromuscular Center, Copenhagen, Denmark

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Ambulatory male
  • Documented SBMA diagnosis confirmed by DNA genetic testing
  • Able to complete six-minute walk test (6MWT)

Exclusion criteria

  • Clinically significant cardiovascular, endocrine, hepatic, renal, pulmonary, gastrointestinal, neurologic, immunologic, malignant, metabolic, psychiatric, or other condition that, in the opinion of the Investigator, precludes the participant's safe participation in the study or would interfere with the study assessments
  • Inability to undergo MRI (mild sedation may be allowed)

Treatment and study plan

NIDO-361

Drug

Tablets containing 100mg of NIDO-361 for oral administration.

Placebo

Drug

Placebo oral tablets

Primary outcomes

  1. Analysis of Thigh and Total Lean Muscle Volume (LMV) [A+B+C]

    Time frame: Baseline, Day 180, Days 360-374 (Last Visit)

    Analysis of thigh included adductors, hamstrings, and quadriceps and total (whole-body) included muscles in the rotator cuff, arm, torso, and leg muscle regions (38 muscles in total). Muscles were categorized according to their fat content as follows: A-muscles were defined as muscle fat fraction (MFF) < 50% and muscle fat infiltration (MFI) < 10%. A-muscles have a low or slightly elevated fat content to a level that can be present in individuals without a neuromuscular disease. B-muscles were defined as MFF < 50% and MFI ≥ 10%. B-muscles have a muscle fat content at a level where disease involvement is likely. C-muscles were defined as MFF ≥ 50%. C-muscles have a muscle fat content where more than 50% of the muscle tissue has been replaced by fat and most of the functional capacity is likely lost.

  2. Number of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs)

    Time frame: Through study completion, an average of 1 year

    Adverse events were coded with MedDRA Dictionary Version 26.1.

  3. Number of Participants Discontinuing Study Drug and Number of Participants' Deaths

    Time frame: Through study completion, an average of 1 year

  4. Total Number of Mild, Moderate, and Severe Adverse Events (AEs) Across All Participants

    Time frame: Through study completion, an average of 1 year

    Adverse events were coded with MedDRA Dictionary Version 26.1.

Secondary outcomes

  1. Change From Baseline to Day 180 and Day 360 in Modified-SBMAFRS (m-SBMAFRS)

    Time frame: Baseline, Day 180, Day 360

    The modified Spinal and Bulbar Muscular Atrophy Functional Rating Scale (m-SBMAFRS) is calculated as the sum of the items for the truncal and lower-limb domains from the SBMAFRS, which is a validated functional rating scale developed from the Amyotrophic Lateral Sclerosis Functional Rating Scale. Each item has five responses options scoring 0 (worst) to 4 (normal). A higher score indicates better functioning. Total range is 0 (worst) to 30 (normal).

  2. Change From Baseline to Day 180 and Day 360 in Two-Minute Walk Test (2MWT)

    Time frame: Baseline, Day 180, Day 360

    2-minute walk test (2MWT) measures the distance traveled (meters) in 2 minutes.

  3. Change From Baseline to Day 180 and Day 360 in 6-Minute Walk Test (6MWT)

    Time frame: Baseline, Day 180, Day 360

    6-minute walk test (6MWT) measures the distance traveled (meters) in 6 minutes.

  4. Change From Baseline to Day 180 and Day 360 in Timed Up and Go (TUG) Test

    Time frame: Baseline, Day 180, Day 360

    The Timed Up and Go Test (TUG) is used to assess mobility and to provide an estimate on balance and risk of falling. Patients are asked to rise from a chair, walk 3 meters, turn around, return to the chair, and sit. The time that it takes to complete the task is recorded. Assistive devices, orthoses, and ankle braces are allowed.

  5. Change From Baseline to Treatment (Days 331 to 360) in Actigraphy-Derived Measurement: Non-Sedentary Behavior

    Time frame: Baseline, Treatment (Days 331 to 360)

    The Actigraph device is a non-invasive research-grade accelerometer based wearable device that was used to objectively measure free-living physical activity. The data from these devices was used to assess and detect changes in physical activity intensity, upper arm movements, and walking patterns.

  6. Change From Baseline to Treatment (Days 331 to 360) in Actigraphy-Derived Measurement: 95th Percentile of 6-Minute Physical Activity Windows

    Time frame: Baseline, Treatment (Days 331 to 360)

    The Actigraph device is a non-invasive research-grade accelerometer based wearable device that was used to objectively measure free-living physical activity. The data from these devices was used to assess and detect changes in physical activity intensity, upper arm movements, and walking patterns.

  7. Change From Baseline to Treatment (Days 331 to 360) in Acitgraphy-Derived Measurement: Maximum Walking Bout Duration

    Time frame: Baseline, Treatment (Days 331 to 360)

    The Actigraph device is a non-invasive research-grade accelerometer based wearable device that was used to objectively measure free-living physical activity. The data from these devices was used to assess and detect changes in physical activity intensity, upper arm movements, and walking patterns.

  8. Change From Baseline to Treatment (Days 331 to 360) in Actigraphy-Derived Measurement: Peak 95th Percentile Cadence

    Time frame: Baseline, Treatment (Days 331 to 360)

    The Actigraph device is a non-invasive research-grade accelerometer based wearable device that was used to objectively measure free-living physical activity. The data from these devices was used to assess and detect changes in physical activity intensity, upper arm movements, and walking patterns.

  9. Change From Baseline to Treatment (Days 331 to 360) in Actigraphy Derived Measurement: Average Breathing Rate

    Time frame: Baseline, Treatment (Days 331 to 360)

    The Actigraph device is a non-invasive research-grade accelerometer based wearable device that was used to objectively measure free-living physical activity. The data from these devices was used to assess and detect changes in physical activity intensity, upper arm movements, and walking patterns.

  10. Change From Baseline to Day 180 and Day 360 in Grip Strength as Measured by Handheld Dynamometer (HHD)

    Time frame: Baseline, Day 180, Day 360

    Grip strength (lbs) is averaged across three trials for the right and left hands separately using a handheld dynamometer (HHD).

Sponsors and collaborators

Lead sponsor

Nido Biosciences, Inc.

Industry

Registry information

Official study title

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of NIDO-361 in Patients With Spinal and Bulbar Muscular Atrophy (SBMA)

Acronym: PIONEER KD

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
May 13, 2024
Registry last updated
Mar 3, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.